Similarly, the PKCβ inhibitor LY379196 prevents hyperglycemia-induced NF-κB activation [262], VCAM-1 expression [262], and apoptosis [263], suggesting PKCβ may be an attractive target to limit diabetes-associated endothelial activation in vivo. Here, NFKB1 is linked to Hyperglycemia.